Retatrutide Reconstitution and Dosage Calculator
Investigational triple GIP, GLP-1 and glucagon receptor agonist with positive phase 3 topline results. Not approved anywhere in the world.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
Investigational — not approved in any country
Retatrutide has reported positive topline results from multiple phase 3 TRIUMPH trials, but it holds no approval from the FDA, EMA, MHRA, TGA or Health Canada. Lilly says it plans an FDA submission in the first quarter of 2027; that is a future application, not an approval. The only lawful human exposure remains a clinical trial or expanded access. In August 2026 the FDA named retatrutide, under the street label “GLP-3R”, in a warning letter as an unapproved new drug.
No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.
Anti-doping: Prohibited at all times. Falls under WADA class S0 (non-approved substances) by definition, because no regulator has approved it for human therapeutic use.
Key facts
- Molecular weight
- 4,731 Da
- Half-life
- About 6 days (phase 1 reported a terminal half-life of 5–7 days)
- Also sold as
- LY3437943, GLP-3, triple agonist
Doses used in published studies
These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.
How good is the evidence?
The strongest evidence of any compound on this page — a published NEJM phase 2 trial and a completed phase 3 programme — but it remains an unapproved investigational drug, and every vial sold at retail is an unapproved new drug of unverified identity and purity.
Retatrutide dosage chart: what the trials actually did
The trial people cite when they quote a retatrutide dose is NCT04881760, 338 participants, published in the New England Journal of Medicine in 2023. Target doses were 1, 4, 8 and 12 mg once weekly for 48 weeks, and the groups assigned 4 mg or more did not start there — they began at 2 mg or 4 mg and escalated every 4 weeks for up to 12 weeks. Mean weight change at 48 weeks ran from −8.7% at 1 mg to −24.2% at 12 mg, against −2.1% on placebo.
Two things follow that get lost when the numbers are repeated without them. First, the impressive figure belongs to a dose nobody reached directly; it is the endpoint of a three-month escalation. Second, these are protocol doses administered under medical supervision with trial monitoring attached, in a population screened for eligibility. They are a record of what was studied, not a schedule, and this site publishes no retatrutide dosing schedule because no regulator anywhere has approved one.
Why there is no such thing as compounded retatrutide
Compounded tirzepatide and semaglutide existed lawfully for a period because a shortage of an approved product allows a compounder to work from the bulk substance under specific conditions. Retatrutide has never been in that position, and cannot be: section 503A permits compounding from a bulk drug substance only where the substance is the subject of an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Retatrutide is none of the three.
So the category error worth avoiding is treating retatrutide as an earlier-stage version of tirzepatide with the same grey-market rules. There is no lawful compounding route, no approved product anywhere in the world to be in shortage of, and in August 2026 the FDA named it — under the street label GLP-3R — in a warning letter as an unapproved new drug, adding that research-use-only labelling does not change that when the seller's own website shows the product is intended for people.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- Published studyNew England Journal of Medicine· 2023Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — a Phase 2 Trial
- Published studyThe Lancet· 2022Urva S et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist — phase 1
- RegulatorFDA· 2026-08-24Warning Letter — Peak Performance Peptides (research-use-only labelling does not exempt an unapproved new drug)
- ReferenceU.S. National Library of MedicineClinicalTrials.gov trial registry
- ReferenceClinicalTrials.gov· 2026-06-03NCT05929066 — TRIUMPH-1 phase 3 trial of retatrutide in obesity or overweight
- ReferenceEli Lilly and Company· 2026-05-21TRIUMPH-1 topline phase 3 results for retatrutide in obesity
- ReferenceEli Lilly and Company· 2026-07-23TRIUMPH-2 and TRIUMPH-3 topline phase 3 results for retatrutide
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- ReferenceNIH / National Center for Biotechnology InformationPubChem compound records (molecular weights and formulae)
- RegulatorFDABulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- RegulatorFDACompounding Risk Alerts